LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
Aurinia announced new analysis from the AURORA 1 Phase 3 study of LUPKYNIS, presented at EULAR 2026. The analysis showed a statistically significant 53% reduction in the risk of renal-related event or death (HR=0.47; p=0.0007) in the safety population of 356 patients.
Key figures
- Drug Name
- LUPKYNIS
- Phase Of Trial
- Phase 3
- P value composite
- 0.0007
- Death risk reduction
- 81%
- Study population size
- 356
- Hazard ratio composite
- 0.47
- Treatment failure risk reduction
- 55%
- Renal event or death risk reduction
- 53%
- Proteinuria worsening risk reduction
- 78%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.